Prima BioMed Ltd (NASDAQ:PBMD)‘s stock had its “buy” rating reaffirmed by investment analysts at Maxim Group in a note issued to investors on Thursday. They presently have a $7.00 price objective on the biotechnology company’s stock. Maxim Group’s target price points to a potential upside of 321.69% from the company’s previous close.

Separately, Zacks Investment Research upgraded Prima BioMed from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Wednesday, May 3rd.

Shares of Prima BioMed (NASDAQ PBMD) traded up 1.81% during midday trading on Thursday, hitting $1.69. The company had a trading volume of 147,972 shares. Prima BioMed has a 12-month low of $1.40 and a 12-month high of $3.26. The firm’s market capitalization is $35.76 million. The firm’s 50-day moving average is $1.67 and its 200-day moving average is $2.23.

TRADEMARK VIOLATION WARNING: “Prima BioMed’s (PBMD) Buy Rating Reaffirmed at Maxim Group” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at

About Prima BioMed

Prima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.

Receive News & Stock Ratings for Prima BioMed Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd and related stocks with our FREE daily email newsletter.